FDA Accepts Shionogi’s Ospemifene NDA in Vulvar and Vaginal Atrophy

Shionogi announced that the FDA has accepted for review the ospemifene new drug application (NDA) for the treatment of vulvar and vaginal atrophy due to menopause, including moderate to severe symptoms of dyspareunia (painful sexual intercourse) and/or vaginal dryness and physiological changes.
MarketWatch